Skip to main content
. 2016 Oct 5;5(1):1719. doi: 10.1186/s40064-016-3404-x

Fig. 3.

Fig. 3

Cost-effectiveness acceptability curve a without renal impact and b with renal impact. ADV adefovir dipivoxil, BSC best supportive care, ETV entecavir, LAM lamivudine, LDT telbivudine, TDF tenofovir